Acesso livre
Acesso livre

Arquivos do dia: Outubro 20, 2021

Estudo do CDC | Vacina da Pfizer mostrou 93% de efetividade contra internações por Covid-19 entre crianças de 12 a 18 anos.

20 Out, 2021 | 12:12h

Effectiveness of Pfizer-BioNTech mRNA Vaccination Against COVID-19 Hospitalization Among Persons Aged 12–18 Years — United States, June–September 2021 – CDC Morbidity and Mortality Weekly Report

 

Comentário no Twitter (fio – clique para saber mais)

 

Estudo randomizado | Interferon não melhora os desfechos de adultos internados com COVID-19.

20 Out, 2021 | 12:10h

Comunicado de imprensa: Interferon does not improve outcomes for hospitalized adults with COVID-19 – NIH News Releases

Estudo original: Efficacy of interferon beta-1a plus remdesivir compared with remdesivir alone in hospitalised adults with COVID-19: a double-bind, randomised, placebo-controlled, phase 3 trial – The Lancet Respiratory Medicine

Estudo de coorte | A efetividade da vacinação heteróloga AstraZeneca (AZ)/mRNA foi mais significativa (68%) do que a vacinação homóloga AZ/AZ (50%) contra Covid-19 sintomática na Suécia.

20 Out, 2021 | 12:08h

Effectiveness of heterologous ChAdOx1 nCoV-19 and mRNA prime-boost vaccination against symptomatic Covid-19 infection in Sweden: A nationwide cohort study – The Lancet Regional Health Europe

Comentário: High effectiveness of mix-and-match COVID-19 vaccines – UMEA University

Conteúdos relacionados:

Study evaluated several heterologous SARS-CoV-2 vaccine regimens; no efficacy data but there was increased antibody production on study days 15 and 29 after booster shots from Moderna and Pfizer.

A primer on what we know about mixing and matching Covid vaccines.

Real-world data shows increased reactogenicity in adults after heterologous compared to homologous prime-boost COVID-19 vaccination.

RCT: Safety and immunogenicity of heterologous vs. homologous prime-boost schedules with an adenoviral vectored and mRNA COVID-19 vaccine.

Another study shows increased immune response with heterologous Oxford-AstraZeneca/mRNA vaccination.

Heterologous Oxford–AstraZeneca and Moderna Vaccination induce increased levels of neutralizing antibody compared to 2 doses of Oxford–AstraZeneca.

Heterologous Oxford–AstraZeneca and BioNTech/Pfizer Vaccination induce increased levels of neutralizing antibody compared to 2 doses of Oxford–AstraZeneca.

[Preprint] Mixing Covid jabs has good immune response, study finds – “The Com-Cov trial looked at the efficacy of either two doses of Pfizer, two of AstraZeneca, or one of them followed by the other. All combinations worked well, priming the immune system”.

Phase 2 RCT: Immunogenicity and reactogenicity of a Pfizer-BioNTech booster in patients that have received a single dose of AstraZeneca vaccine – “BNT162b2 (Pfizer) given as a second dose in individuals prime vaccinated with ChAdOx1-S (AstraZeneca) induced a robust immune response, with an acceptable and manageable reactogenicity profile”.

Lab study shows heterologous AstraZeneca/Pfizer vaccination produces strong immune response against SARS-CoV-2 Delta variant.

Lab study shows a heterologous AstraZeneca + Pfizer immunization strategy provides stronger immunogenicity against Covid compared to homologous AZ + AZ or Pfizer + Pfizer strategies.

RCT: Mixing 2 different Covid vaccines is associated with increased risk of side effects.

 

Comentário no Twitter

 

Deve-se misturar e combinar a dose de reforço da vacina?

20 Out, 2021 | 12:06h

Should You Mix and Match Your Booster Shot? – The Atlantic

Conteúdos relacionados:

Study evaluated several heterologous SARS-CoV-2 vaccine regimens; no efficacy data but there was increased antibody production on study days 15 and 29 after booster shots from Moderna and Pfizer.

A primer on what we know about mixing and matching Covid vaccines.

Real-world data shows increased reactogenicity in adults after heterologous compared to homologous prime-boost COVID-19 vaccination.

RCT: Safety and immunogenicity of heterologous vs. homologous prime-boost schedules with an adenoviral vectored and mRNA COVID-19 vaccine.

Another study shows increased immune response with heterologous Oxford-AstraZeneca/mRNA vaccination.

Heterologous Oxford–AstraZeneca and Moderna Vaccination induce increased levels of neutralizing antibody compared to 2 doses of Oxford–AstraZeneca.

Heterologous Oxford–AstraZeneca and BioNTech/Pfizer Vaccination induce increased levels of neutralizing antibody compared to 2 doses of Oxford–AstraZeneca.

[Preprint] Mixing Covid jabs has good immune response, study finds – “The Com-Cov trial looked at the efficacy of either two doses of Pfizer, two of AstraZeneca, or one of them followed by the other. All combinations worked well, priming the immune system”.

Phase 2 RCT: Immunogenicity and reactogenicity of a Pfizer-BioNTech booster in patients that have received a single dose of AstraZeneca vaccine – “BNT162b2 (Pfizer) given as a second dose in individuals prime vaccinated with ChAdOx1-S (AstraZeneca) induced a robust immune response, with an acceptable and manageable reactogenicity profile”.

Lab study shows heterologous AstraZeneca/Pfizer vaccination produces strong immune response against SARS-CoV-2 Delta variant.

Lab study shows a heterologous AstraZeneca + Pfizer immunization strategy provides stronger immunogenicity against Covid compared to homologous AZ + AZ or Pfizer + Pfizer strategies.

RCT: Mixing 2 different Covid vaccines is associated with increased risk of side effects.

[Preprint] Estudo observacional no Brasil mostrou que a efetividade ajustada da vacina da J&J foi de 50,9% contra Covid-19 sintomática, 72,9% para internações, 92,5% para admissão em UTI, 88,7% para ventilação mecânica e 90,5% para morte.

20 Out, 2021 | 12:05h

Vaccine effectiveness of Ad26.COV2.S against symptomatic COVID-19 and clinical outcomes in Brazil: a test-negative study design – medRxiv

Covid-19: nova mutação da variante Delta sob observação atenta no Reino Unido.

20 Out, 2021 | 12:03h

Covid-19: New mutation of Delta variant under close watch in UK – BBC

Estratégia da Global Initiative for Asthma (GINA) 2021 – Resumo executivo e racional para mudanças importantes.

20 Out, 2021 | 12:02h

Global Initiative for Asthma (GINA) Strategy 2021 – Executive summary and rationale for key changes – European Respiratory Journal

Revisão sistemática | Agentes anti-interleucina-13 ou anti-interleucina-4 podem ser adequados para adultos com asma descontrolada moderada/grave que não responderam a outros tratamentos.

20 Out, 2021 | 12:01h

Anti‐interleukin‐13 and anti‐interleukin‐4 agents versus placebo, anti‐interleukin‐5 or anti‐immunoglobulin‐E agents, for people with asthma – Cochrane Library

Resumo: Anti-interleukin-13 or anti-interleukin-4 agents versus placebo, anti-interleukin-5 or anti-immunoglobulin-E agents, for children and adults with asthma – Cochrane Library

 

Comentário no Twitter (fio – clique para saber mais)

 

Sete recomendações de políticas da OMS sobre a construção de sistemas de saúde resilientes.

20 Out, 2021 | 11:59h

Comunicado de imprensa: WHO’s 7 policy recommendations on building resilient health systems – World Health Organization

Posicionamento científico da OMS: Building health systems resilience for universal health coverage and health security during the COVID-19 pandemic and beyond

 

Comentário no Twitter (fio – clique para saber mais)

 

Resumo de Política da OMS | A necessidade urgente de se implementar o manejo de sangue do paciente.

20 Out, 2021 | 11:58h

The urgent need to implement patient blood management: policy brief – World Health Organization

Mantenha-se atualizado em sua especialidade

 

Escolha quantas especialidades quiser.